MedTrace Logo

Pre vs Post Block in Total Knee Arthroplasty (TKA)

NCT05974501 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-02-12

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee arthroplasty can be observed with the substitution of a post operative adductor canal block for a preoperative adductor canal block in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Conditions

Interventions

DRUG

Dexamethasone

Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling

DRUG

Acetaminophen

1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively

DRUG

Lyrica

Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively

DRUG

Celebrex

200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively

DRUG

Meloxicam

30mg administered via IV once postoperatively within 24 hours for pain and swelling

DRUG

Oxycodone

5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively

DRUG

Ropivacaine

20 milliliters Ropivacaine 0.2% administered via injection perioperatively.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Victor H. Hernandez, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-29
Primary Completion
2024-01-22
Completion
2024-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05974501 on ClinicalTrials.gov